Clinical trial
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
NCT00070070 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00070070 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas |
| Official title | NY-ESO-1 Protein Immunization of Post-Cystectomy or Post-Nephroureterectomy Patients With Transitional Cell Carcinomas |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Transitional Cell Carcinoma |
| Intervention type | Biological |
| Interventions | TICE®-strain BCG, NY-ESO-1 protein, sargramostim |
| Enrollment | 6 |
| Start date | Oct 28, 2003 |
| Primary completion | Jan 3, 2006 |
| Completion | Sep 30, 2013 |
| First posted | Oct 7, 2003 |
| Last update posted | Oct 12, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: